Abstract
Adenosine A2A receptor antagonists are of great interest in the treatment for Parkinson’s disease. In this study, we combined extensive pharmacophore modeling and quantitative structure-activity relationship (QSAR) analysis to explore the structural requirements for potent Adenosine A2A antagonists. Genetic function algorithm (GFA) joined with k nearest neighbor (kNN) analyses were applied to build predictive QSAR models. Successful pharmacophores were complemented with exclusion spheres to improve their receiver operating characteristic curve (ROC) profiles. Best QSAR models and their associated pharmacophore hypotheses were validated by identification of several novel Adenosine A2A antagonist leads retrieved from the National Cancer Institute (NCI) structural database. The most potent hit illustrated IC50 value of 545.7 nM.
[Display omitted]
•Adenosine A2A is a clinically validated target for neurodegenerative diseases.•Pharmacophore combined with QSAR was applied to model Adenosine A2A inhibitors.•Self-consistent and predictive QSAR models were built.•Several new potent Adenosine A2A antagonists were identified.